SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

Search

Smith & Nephew PLC

Abierto

1,328 -0.6

Resumen

Variación precio

24h

Actual

Mínimo

1323

Máximo

1350.5

Métricas clave

By Trading Economics

Ingresos

296M

Ventas

3B

P/B

Media del Sector

32.354

48.535

BPA

0.429

Rentabilidad por dividendo

2.89

Margen de beneficios

9.895

Empleados

17,000

EBITDA

723M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+11.53% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.89%

3.96%

Próximas Ganancias

2 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

11B

Apertura anterior

1328.6

Cierre anterior

1328

Smith & Nephew PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb 2026, 22:36 UTC

Ganancias

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb 2026, 22:32 UTC

Ganancias

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb 2026, 23:58 UTC

Charlas de Mercado
Ganancias

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb 2026, 23:58 UTC

Charlas de Mercado
Ganancias

Global Energy Roundup: Market Talk

23 feb 2026, 23:47 UTC

Charlas de Mercado

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb 2026, 23:43 UTC

Charlas de Mercado

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb 2026, 23:40 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb 2026, 23:40 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb 2026, 23:40 UTC

Charlas de Mercado

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb 2026, 23:40 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb 2026, 23:39 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb 2026, 23:31 UTC

Ganancias

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb 2026, 23:31 UTC

Ganancias

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb 2026, 23:28 UTC

Ganancias

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb 2026, 23:28 UTC

Ganancias

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb 2026, 23:28 UTC

Ganancias

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb 2026, 23:27 UTC

Ganancias

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb 2026, 23:24 UTC

Charlas de Mercado

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb 2026, 22:31 UTC

Ganancias

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb 2026, 22:24 UTC

Ganancias

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb 2026, 22:21 UTC

Ganancias

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb 2026, 22:21 UTC

Ganancias

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb 2026, 22:20 UTC

Ganancias

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparación entre iguales

Cambio de precio

Smith & Nephew PLC previsión

Precio Objetivo

By TipRanks

11.53% repunte

Estimación a 12 Meses

Media 1,490.57 GBX  11.53%

Máximo 1,650 GBX

Mínimo 1,290 GBX

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Smith & Nephew PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

5

Comprar

2

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat